September, 2014, Media Release

Award Winners

The Cancer Institute NSW Premier's Awards for Outstanding Cancer Research is an annual event that celebrates excellence and innovation in cancer research. Seven awards were presented to those leading the way in their field, including Ursula Sansom-Daly, who recieved the 'Rising Star' PhD Award and Dr Claire Wakefield, who recieved the 'Outstanding Cancer Research Fellow of the Year' award. 

New DFMO Trial at SCH

Dr David Ziegler was interviewed about the launch of the new DFMO Trial and SCH being the only Hospital in Australia to host the international study into a new treatment for neuroblastoma.

June, 2014, Media Release

Rory's story on 60 Minutes

60 Minutes on Channel 9 have produced a documentary on cancer patient Rory's plight against the disease, as part of the Gold Telethon appeal. Gold Telethon is the major annual fundraising event for Sydney Children's Hospital, Randwick. It raises funds to buy life-saving equipment, fund research and deliver vital services to help our young patients.


 September 2013, Media Release

Australian researchers help uncover genetic cause of childhood leukaemia

Australian researchers at the Children’s Cancer Institute Australia (CCIA) and Sydney Children’s Hospital are part of an international research collaboration that has discovered a genetic link specific to the risk of childhood leukaemia for the first time.

The paper has been published in Nature Genetics and is the first study to find an inheritable gene that can cause acute lymphoblastic leukaemia, the most common childhood cancer.

Undertaken by a worldwide team of researchers and supported in Australia by the Sovereign Hospitaller Order of Saint John of Jerusalem, Knights of Malta, the study observes families in which multiple cases of acute lymphoblastic leukaemia have been diagnosed.

Dr David Ziegler, Clinical Research Fellow at CCIA, paediatric oncologist at Sydney Children’s Hospital and lead Australian author of the paper, says the discovery has identified an important genetic cause of acute lymphoblastic leukaemia and will ultimately help find better ways to treat it.

“Leukaemia cells often contain many different genetic mutations, making it difficult to detect which ones actually cause the leukaemia,” says Dr Ziegler.

“We approached this study differently by looking for mutations carried by individuals who came from rare families in which there were multiple cases of childhood leukaemia. The genetic mutation that was discovered is a critical driving factor and can be used as a fresh goal for the development of new therapies.

“This discovery unveils the possibility of a genetic test for acute lymphoblastic leukaemia, similar to that conducted for breast cancer, which could allow affected families to prevent childhood leukaemia in future generations,” continues Dr Ziegler.

Dr Ziegler hopes that ongoing research will identify other genes that cause acute lymphoblastic leukaemia and reveal how these inherited factors can be targeted, allowing for the development of improved therapies and higher cure rates.